2011
DOI: 10.2174/138920111796117300
|View full text |Cite
|
Sign up to set email alerts
|

Anti-Angiogenic Peptides for Cancer Therapeutics

Abstract: Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
122
0
1

Year Published

2013
2013
2016
2016

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 141 publications
(123 citation statements)
references
References 120 publications
0
122
0
1
Order By: Relevance
“…It has been systemically implicated in tumor therapy by reducing the number of newly-formed blood vessels (Rosca et al, 2011). Results from these clinical studies have proven the safety of this drug.…”
Section: Discussionmentioning
confidence: 99%
“…It has been systemically implicated in tumor therapy by reducing the number of newly-formed blood vessels (Rosca et al, 2011). Results from these clinical studies have proven the safety of this drug.…”
Section: Discussionmentioning
confidence: 99%
“…These suggest that modest but sustained increases in angiogenic inhibitors (angiostatin or endostatin) may be capable of significantly inhibiting tumor growth. Peptides have emerged as important therapeutics that is rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity (36). Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin and endostatin), several peptides (including endostatin mimics and gelatinase inhibitory peptide CTTHWGFTLC) have shown promise in preclinical and clinical studies for cancer (23,37).…”
Section: Discussionmentioning
confidence: 99%
“…Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin and endostatin), several peptides (including endostatin mimics and gelatinase inhibitory peptide CTTHWGFTLC) have shown promise in preclinical and clinical studies for cancer (23,37). Angiogenesis inhibitors, particularly polypeptides or endogenous peptides, may become the safest and least toxic therapy for diseases associated with abnormal angiogenesis (36,37). However, the use of peptides in vivo has largely been limited by their extremely short half-life.…”
Section: Discussionmentioning
confidence: 99%
“…Peptides can be used as drugs, hormones, or immunization agents (vaccines) (Sah et al 2015). The biological effects include inhibition of tumor vasculature growth (angiogenesis), alterations in protein-protein interaction, changes in gene expression, and apoptosis, among others (Rosca et al 2011;Walensky et al 2004;Zheng et al 2011).…”
Section: Peptide-based Strategies For Cancermentioning
confidence: 99%